About N-acetylgalactosamine kinase
N-acetylgalactosamine kinase (GALK2) is a protein
from Homo sapiens identified by UniProt accession
Q01415, 458 residues long.
MolForge cross-references it against 0 known binders and
63 disease associations.
Target properties
| Protein name | N-acetylgalactosamine kinase |
| UniProt accession | Q01415 |
| Gene | GALK2 |
| Organism | Homo sapiens |
| Length | 458 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (63)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.35
- FEV/FVC ratio · score 0.26
- mean platelet volume · score 0.23
- cortical thickness · score 0.19
- psoriatic arthritis · score 0.15
- multiple sclerosis · score 0.12
- Alzheimer disease · score 0.12
- lysosomal storage disease · score 0.12
- Parkinson disease · score 0.12
- thyroid stimulating hormone measurement · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q01415-F1 | alphafold | PREDICTED | 94.90 | — |
Amino-acid sequence (458 residues)
MATESPATRR VQVAEHPRLL KLKEMFNSKF GSIPKFYVRA PGRVNIIGEH IDYCGYSVLP MAVEQDVLIA VEPVKTYALQ LANTNPLYPD FSTSANNIQI DKTKPLWHNY FLCGLKGIQE HFGLSNLTGM NCLVDGNIPP SSGLSSSSAL VCCAGLVTLT VLGRNLSKVE LAEICAKSER YIGTEGGGMD QSISFLAEEG TAKLIEFSPL RATDVKLPSG AVFVIANSCV EMNKAATSHF NIRVMECRLA AKLLAKYKSL QWDKVLRLEE VQAKLGISLE EMLLVTEDAL HPEPYNPEEI CRCLGISLEE LRTQILSPNT QDVLIFKLYQ RAKHVYSEAA RVLQFKKICE EAPENMVQLL GELMNQSHMS CRDMYECSCP ELDQLVDICR KFGAQGSRLT GAGWGGCTVS MVPADKLPSF LANVHKAYYQ RSDGSLAPEK QSLFATKPGG GALVLLEA
Explore N-acetylgalactosamine kinase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets